Safety of guselkumab with and without prior TNF-α inhibitor treatment: pooled results across four studies in patients with psoriatic arthritis

Eitemau Tebyg

• Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
  gan: Coates, LC, et al.
  Cyhoeddwyd: (2024)
• The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled tria
  gan: Ritchlin, CT, et al.
  Cyhoeddwyd: (2023)
• Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
  gan: Coates, LC, et al.
  Cyhoeddwyd: (2024)
• Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis
  gan: Coates, L, et al.
  Cyhoeddwyd: (2022)
• Guselkumab provides sustained domain-specific and comprehensive efficacy as assessed using composite endpoints in patients with active psoriatic arthritis free
  gan: Coates, LC, et al.
  Cyhoeddwyd: (2021)